Antidote Therapeutics' Grant

Antidote Therapeutics raised a round of funding on April 02, 2017. Investors include National Institutes of Health.

Antidote Therapeutics is assessing the protein properties of a novel nicotine degrading enzyme and its suitability for use as a smoking cessation treatment.…

Articles about Antidote Therapeutics' Grant: